School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Waihuan Road, Guangzhou Higher Education Mega Center, No. 232, Guangzhou, 510006, Guangdong, China.
Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
BMC Complement Med Ther. 2024 Aug 10;24(1):298. doi: 10.1186/s12906-024-04588-x.
Danggui Shaoyao San (DSS), a frequently prescribed Chinese medicine formula, has demonstrated clinical efficacy in the treatment of Alzheimer's disease (AD). This study aims to explore the differences in therapeutic effects of DSS and its disassembled prescriptions, Suangan (SG) and Xingan (XG), in treating Alzheimer's Disease and the mechanism of DSS recovering autophagy in AD.
A network pharmacology strategy was employed to delineate the bioactive constituents, associated targets, and regulatory mechanisms of DSS in AD, encompassing in silico target forecasting, the generation and scrutiny of PPI networks, alongside GO and KEGG-based pathway elucidation. An AD mouse model, induced by intracerebroventricular injection of Aβ, was used to evaluate the therapeutic effects of DSS and its disassembled prescriptions on AD. Cognitive function was evaluated using the Morris water maze. Expression levels of inflammatory cytokines were quantified via RT-qPCR and ELISA. Western blotting was used to detect the expression of proteins related to AD pathological markers and the AMPK/mTOR signaling pathway.
50 active compounds and 718 HUB genes were screened from relevant databases and literature. KEGG and GO analyses indicated that DSS's potential mechanisms against AD involved the AMPK/mTOR signaling pathway and mitophagy. In vivo animal model, the results demonstrated that DSS, SG, and XG treatments improved cognitive function and ameliorated neuroinflammation in mice. Additionally, they alleviated the pathological changes of neuronal cells. These treatments also increased the protein level of PSD-95, and decreased levels of APP and p-Tau. Among them, DSS exhibited the best efficacy. Furthermore, DSS, SG, and XG upregulated the expression of LC3, Beclin1, and p-AMPK, while decreasing the expression of P62 and p-mTOR.
DSS, SG, and XG were found to ameliorate AD-related pathological symptoms in Aβ-injected mice, likely through the AMPK/mTOR autophagy signaling pathway.
当归芍药散(DSS)是一种常用的中药方剂,已被证明对阿尔茨海默病(AD)具有临床疗效。本研究旨在探讨 DSS 及其拆方芍药甘草汤(SG)和逍遥散(XG)治疗 AD 的疗效差异及其恢复 AD 自噬的作用机制。
采用网络药理学策略,对 DSS 治疗 AD 的生物活性成分、相关靶点和作用机制进行了描绘,包括计算机预测靶标、PPI 网络的生成和筛选,以及 GO 和 KEGG 通路分析。采用 Aβ 脑室内注射诱导 AD 小鼠模型,评价 DSS 及其拆方对 AD 的治疗作用。采用 Morris 水迷宫评价认知功能。采用 RT-qPCR 和 ELISA 检测炎性细胞因子表达水平。采用 Western blot 检测 AD 相关病理标志物和 AMPK/mTOR 信号通路相关蛋白的表达。
从相关数据库和文献中筛选出 50 个活性化合物和 718 个 HUB 基因。KEGG 和 GO 分析表明,DSS 治疗 AD 的潜在机制涉及 AMPK/mTOR 信号通路和线粒体自噬。体内动物模型结果表明,DSS、SG 和 XG 治疗可改善小鼠的认知功能,减轻神经炎症,改善神经元细胞的病理变化。这些治疗方法还增加了 PSD-95 的蛋白水平,降低了 APP 和 p-Tau 的水平。其中,DSS 的疗效最好。此外,DSS、SG 和 XG 上调了 LC3、Beclin1 和 p-AMPK 的表达,降低了 P62 和 p-mTOR 的表达。
DSS、SG 和 XG 可改善 Aβ 注射小鼠的 AD 相关病理症状,可能通过 AMPK/mTOR 自噬信号通路。